CALC
CalciMedica, Inc. Common StockKey Statistics
About CalciMedica, Inc. Common Stock
CalciMedica, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies targeting calcium-dependent pathways for the treatment of acute and chronic conditions. Its lead candidate, CM4620, is designed to alleviate severe muscle cramps associated with sickle cell disease, highlighting the company’s commitment to addressing critical unmet medical needs. CalciMedica leverages a proprietary technology platform to create innovative calcium modulators and has a robust pipeline supported by an experienced management team and strategic partnerships aimed at accelerating clinical development. With a focus on transforming treatment landscapes, CalciMedica presents a distinctive investment opportunity in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.19M |
| Operating Margin | 0.00% |
| Return on Equity | -399.50% |
| Return on Assets | -81.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.43 |
| Price-to-Book | 7.13 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $15.80M |
| Float | $8.94M |
| % Insiders | 21.53% |
| % Institutions | 40.23% |
Historical Volatility
Volatility is currently contracting